Repligen Corporation RGEN

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Over the past six months, Repligen has been a great trade, beating the S&P 500 by 18.1%. Its stock price has climbed to $168.43, representing a healthy 31.7% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Repligen stock has delivered a strong 1 year gain, yet the broader valuation checks and recent history raise questions about how much upside is left. The intrinsic value estimate from a Discounted Cash Flow (DCF) view is close to the current share price, while market-based multiples lean more expensive. Over 5 years, Repligen shares have declined about 42%, which points to a difficult longer term journey despite a healthier recent rebound. The valuation story now hinges on whether Repligen...